<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924868</url>
  </required_header>
  <id_info>
    <org_study_id>2020/159</org_study_id>
    <secondary_id>2020-005901-16</secondary_id>
    <nct_id>NCT04924868</nct_id>
  </id_info>
  <brief_title>Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis</brief_title>
  <acronym>OSOPOLAR</acronym>
  <official_title>Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis, a Double-blind Multicenter Randomized-controlled Trial. OSOPOLAR Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario de Alicante</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario de Alicante</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis is a common disease (3rd cause of hospital admission for digestive&#xD;
      causes), which is associated with significant patient suffering, a 2-4% probability of death&#xD;
      and considerable healthcare costs. Sixty percent of acute pancreatitis are due to the&#xD;
      presence of stones in the gallbladder. The risk of suffering another acute biliary&#xD;
      pancreatitis (ABP, that is to say, pancreatitis due to gallstones) or of other biliary&#xD;
      complications in the following weeks or months is high (20% or greater) if measures are not&#xD;
      taken to avoid it, being surgical removal of the gallbladder the most effective.&#xD;
      Unfortunately, most Spanish centers have a surgical waiting list that makes gallbladder&#xD;
      surgery unfeasible in a period of less than weeks or months, which is why readmission for&#xD;
      biliary problems derived from the stones is a common problem. This, of course, causes danger&#xD;
      and great stress and anger for patients affected by these complications on the waiting list,&#xD;
      damaging their relationship with the health system and it is linked to increased cost. In&#xD;
      addition, there is a very vulnerable group, those patients who due to age or serious diseases&#xD;
      cannot undergo gallbladder surgery but have a high probability of suffering biliary problems&#xD;
      due to the stones they have.&#xD;
&#xD;
      Ursodeoxycholic acid (UDCA) is very safe drug which is used to dissolve gallstones, but its&#xD;
      role in preventing biliary complications after ABP has not been studied adequately so it is&#xD;
      not frequently used. Our objective is to investigate if UDCA is useful in this scenario,&#xD;
      which would avoid suffering and adverse consequences for the patient and reduce the&#xD;
      consumption of resources.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complication due to gallstones</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Composite endpoint: incidence of any of the following: acute pancreatitis, acute cholangitis, acute cholecystitis, biliary colic (with or without choledocholithiasis) Definitions are provided in &quot;Secondary Outcome Measures&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse of acute pancreatitis</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>New episode of acute pancreatitis after recruitment Definition of acute pancreatitis (revised Atlanta classification): 2 or more of the following criteria: A) Typical pancreatitis pain, B) Amylase and/or lipase higher than 3 times the upper level of normality, C) Imaging compatible with acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute cholangitis</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Acute cholangitis after recruitment&#xD;
Acute cholangitis definition (Tokyo 2018 guidelines):&#xD;
A. Systemic inflammation: A-1. Fever and/or shaking chills; A-2. Laboratory data: evidence of inflammatory response B. Cholestasis: B-1. Jaundice; B-2. Laboratory data: abnormal liver function tests C. Imaging: C-1. Biliary dilatation; C-2. Evidence of the etiology on imaging (stricture, stone, stent etc.) Suspected diagnosis: one item in A + one item in either B or C Definite diagnosis: one item in A, one item in B and one item in C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute cholecystitis</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Acute cholecystitis after recruitment&#xD;
Acute cholecystitis definition (Tokyo 2018 guidelines):&#xD;
A. Local signs of inflammation: (1) Murphy's sign, (2) RUQ mass/pain/tenderness B. Systemic signs of inflammation: (1) Fever, (2) elevated CRP, (3) elevated WBC count C. Imaging findings: Imaging findings characteristic of acute cholecystitis Suspected diagnosis: one item in A + one item in B Definite diagnosis: one item in A + one item in B + C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biliary colic, with or without choledocholithiasis</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Biliary colic after recruitment Biliary colic definition: typical biliary colic pain. Choledocholithiasis: presence of stones or biliary sludge in the common bile duct according to imaging or endoscopic retrograde cholangio-pancreatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of ursodeoxycholic acid in treating gallstones</measure>
    <time_frame>Abdominal ultrasonography will be performed at 6 and 12 months after recruitment unless cholecystectomy is performed</time_frame>
    <description>Decrease or elimination of gallstones according to ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ C30 questionnaire</measure>
    <time_frame>Measurement at 1, 3, 6, 9 and 12 months after recruitment</time_frame>
    <description>EORTC-QLQ C30 questionnaire as a measure of Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay during follow-up</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Number of days admitted due to symptomatic gallstone disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit stay during follow-up</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Number of days admitted in the intensive care unit due to symptomatic gallstone disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Adverse events due to ursodeoxycolic acid or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to emergency room or hospital admissions due to symptomatic gallstone disease</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Number of visits to emergency room or hospital admissions due to symptomatic gallstone disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for endoscopic retrograde cholangio-pancreatography (ERCP) during follow-up</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Need for ERCP due to choledocholithiasis or acute cholangitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for gallbladder endoscopic or percutaneous drainage during follow-up</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Need for gallbladder endoscopic or percutaneous drainage due to acute cholecystitis or cholangitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for drainage of collections and abscesses</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Need for drainage of collections and abscesses (liver abscess, symtomatic pancreatic or peripancreatic collections not related to the index acute pancreatitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of organ failure during follow-up</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Organ failure definition (revised Atlanta classification): PaO2/FIO2&lt;300, Creatinine &gt;=1.9 mg/dl and/or systolic blood pressure &lt;90mmHg despite fluid resuscitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Death during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for urgent cholecystectomy</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Need for urgent cholecystectomy for acute gallbladder complication, mainly acute cholecystitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surgical necrosectomy</measure>
    <time_frame>From recruitment to cholecystectomy or up to 1 year after recruitment if cholecystectomy is not performed</time_frame>
    <description>Need for surgical necrosectomy, mainly after infection of pancreatic necrosis (not related to the index acute pancreatitis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Acute Pancreatitis Due to Gallstones</condition>
  <arm_group>
    <arm_group_label>UDCA (Ursodeoxycholic Acid) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving Ursodeoxycholic Acid, capsules containing 300 mg, 10 mg/Kg per day:&#xD;
Patients 40 to 70 kg: 2 capsules/day &gt;70 to 100 Kg: 3 capsules/day &gt;100 kg: 4 capsules/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules containing placebo, indistinguishable from active treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>Ursodeoxycholic Acid will be administered to patients in the UDCA group as a prophylactic measure of future complications associated to gallstones</description>
    <arm_group_label>UDCA (Ursodeoxycholic Acid) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old or older&#xD;
&#xD;
          -  Hospital admission due to acute pancreatitis (definition: at least 2 of the following&#xD;
             criteria: A) Typical pancreatitis pain, B) Amylase and/or lipase higher than 3 times&#xD;
             the upper level of normality, C) Imaging compatible with acute pancreatitis&#xD;
&#xD;
          -  Presence of gallstones according to any imaging technique&#xD;
&#xD;
          -  Patient informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cholecystectomy and/or endoscopic retrograde cholangio-pancreatography and / or&#xD;
             endoscopic cholecystostomy prior to recruitment&#xD;
&#xD;
          -  Recurrent acute pancreatitis (1 or more previous episodes of pancreatitis of any&#xD;
             origin)&#xD;
&#xD;
          -  Current waiting list for cholecystectomy for acute biliary pancreatitis at that center&#xD;
             less than 30 days&#xD;
&#xD;
          -  Randomization more than 3 days after hospital discharge for acute pancreatitis&#xD;
&#xD;
          -  Ursodeoxycholic acid (UDCA) consumption in the last 5 years or previous UDCA failure&#xD;
             to dissolve lithiasis&#xD;
&#xD;
          -  Allergy, intolerance or presence of contraindications to UDCA (contraindicated in&#xD;
             patients with active gastric or duodenal ulcer, liver or intestinal disorders that&#xD;
             interfere with the enterohepatic circulation of bile salts and lactation)&#xD;
&#xD;
          -  Presence of choledocholithiasis diagnosed by imaging tests prior to randomization&#xD;
&#xD;
          -  Active alcoholism greater than or equal to 5 daily alcoholic drinks in men or 3 in&#xD;
             women or high clinical suspicion of clinically significant alcoholism&#xD;
&#xD;
          -  Recent history of significant therapeutic non-compliance or social problem that makes&#xD;
             follow-up difficult&#xD;
&#xD;
          -  Hypertriglyceridemia greater than 400 mg / dL during admission or history of poorly&#xD;
             controlled severe hypertriglyceridemia&#xD;
&#xD;
          -  Chronic pancreatitis (pancreatic calcifications and / or Wirsung duct 4 or more mm)&#xD;
&#xD;
          -  Pancreatic cystic lesions not attributed to the pancreatitis itself&#xD;
&#xD;
          -  Wirsung duct stenosis&#xD;
&#xD;
          -  Primary hyperparathyroidism&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique De Madaria, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alicante General University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia Vaillo</last_name>
    <phone>(+34) 661302932</phone>
    <email>vailloalicia@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan En Domínguez Muñoz, Medicine</last_name>
      <email>juanenrique.dominguez@usc.es</email>
    </contact>
    <investigator>
      <last_name>Juan En Domínguez Muñoz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Irene Pascual Sánchez</last_name>
      <email>irenepascuals@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Irene Pascual Sánchez, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias.</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Eu Lauret Braña</last_name>
      <email>meugelb@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Eu Lauret Braña, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Silvia Salord Vila, Medicine</last_name>
      <email>ssalord@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Silvia Salord Vila, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Corporació Sanitària Parc Taulí de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Pa Llovet Soto, Medicine</last_name>
      <email>laura.llovet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laura Pa Llovet Soto, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Claudia Sánchez Marín</last_name>
      <email>claudiasanchez370@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Claudia Sánchez Marín, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol,</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Robin Rivera Irigoin, Medicine</last_name>
      <email>robinriverai@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Robin Rivera Irigoin, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Unversidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Cristina Carretero Ribón, Medicine</last_name>
      <email>ccarretero@unav.es</email>
    </contact>
    <investigator>
      <last_name>Cristina Carretero Ribón, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Alicante</city>
        <state>Valencia</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabel Pascual Moreno, Medicine</last_name>
      <email>isabel.pascual-moreno@uv.es</email>
    </contact>
    <investigator>
      <last_name>Isabel Pascual Moreno, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Emma Martínez Moneo</last_name>
      <email>EMMA.MARTINEZMONEO@osakidetza.eus</email>
    </contact>
    <investigator>
      <last_name>Emma Martínez Moneo, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Alicia Vaillo</last_name>
      <phone>0034 661302932</phone>
      <email>vailloalicia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Enrique de Madaria, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Univerisitario Vall D´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesc Xa Molero Richard, Medicine</last_name>
      <email>xavier.molero@vhir.org</email>
    </contact>
    <investigator>
      <last_name>Francesc Xa Molero Richard, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínio San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio M Caballero, Medicine</last_name>
      <email>ogy1492@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio M Caballero, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana García García De Paredes, Medicine</last_name>
      <email>anaggparedes@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana García García de Paredes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Francisco González</last_name>
      <email>mariamedico@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Francisco González, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Guillermo García Rayado, Medicine</last_name>
      <email>guillermogarcia7@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Guillermo García Rayado, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Vanesa Bernal Monterde</last_name>
      <email>vbernalm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vanesa Bernal Monterde, Medicine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario de Alicante</investigator_affiliation>
    <investigator_full_name>Enrique de-Madaria</investigator_full_name>
    <investigator_title>Coordinator of Biliary-Pancreatic Unit.</investigator_title>
  </responsible_party>
  <keyword>Acute pancreatitis</keyword>
  <keyword>Gallstones</keyword>
  <keyword>Ursodeoxycholic Acid</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Gallstones</mesh_term>
    <mesh_term>Cholelithiasis</mesh_term>
    <mesh_term>Cholecystolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

